Heparin acts synergistically with interleukin-11 to induce STAT3 activation and in vitro osteoclast formation
Open Access
- 1 October 2002
- journal article
- Published by American Society of Hematology in Blood
- Vol. 100 (7) , 2530-2536
- https://doi.org/10.1182/blood.v100.7.2530
Abstract
We have previously demonstrated that long-term heparin treatment causes cancellous bone loss in rats due in part to an increase in the number of osteoclasts lining the trabecular bone surface. In the present study, we investigated this phenomenon by examining the ability of heparin to synergistically enhance interleukin-11 (IL-11)–induced osteoclast formation. Treatment of murine calvaria and bone marrow cells with IL-11 was found to induce the formation of tartrate-resistant acid phosphatase-positive (TRAP+) multinucleated cells (MNCs) in a dose-dependent fashion. No effect was seen when cocultures were treated with heparin alone. However, when cocultures were treated with both IL-11 and heparin, IL-11's ability to induce TRAP+ MNC formation was enhanced 6-fold. In an attempt to resolve the mechanism responsible for this effect, we examined the ability of heparin to influence IL-11 signaling using murine calvaria cells. Heparin was found to enhance both IL-11–induced STAT3-DNA complex formation and transactivation without altering either STAT3 (signal transducer and activator of transcription-3) tyrosine or serine phosphorylation. Heparin was also found to enhance IL-11's ability to induce the expression of both receptor activator of nuclear factor–κB ligand (RANKL) and glycoprotein (gp) 130. When taken together, these findings suggest a plausible mechanism by which heparin may cause increased osteoclastogenesis and therefore bone loss when administered long-term.Keywords
This publication has 50 references indexed in Scilit:
- STIMULATION OF OSTEOCLAST DIFFERENTIATION IN VITRO BY MOUSE ONCOSTATIN M, LEUKAEMIA INHIBITORY FACTOR, CARDIOTROPHIN-1 AND INTERLEUKIN 6: SYNERGY WITH DEXAMETHASONECytokine, 2000
- STAT3 Activation in Stromal/Osteoblastic Cells Is Required for Induction of the Receptor Activator of NF-κB Ligand and Stimulation of Osteoclastogenesis by gp130-utilizing Cytokines or Interleukin-1 but Not 1,25-Dihydroxyvitamin D3 or Parathyroid HormoneJournal of Biological Chemistry, 1999
- The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures.The Journal of Experimental Medicine, 1996
- In vivo effects of interleukin‐11 and stem cell factor in combination with erythropoietin in the regulation of erythropoiesisBritish Journal of Haematology, 1995
- Requirement of Serine Phosphorylation for Formation of STAT-Promoter ComplexesScience, 1995
- Stat3: a STAT Family Member Activated by Tyrosine Phosphorylation in Response to Epidermal Growth Factor and Interleukin-6Science, 1994
- Interleukin-11: a new cytokine critical for osteoclast development.Journal of Clinical Investigation, 1994
- Cytokine signal transductionPublished by Elsevier ,1994
- Up‐regulation of the interleukin‐6‐signal transducing protein (gp130) by interleukin‐6 and dexamethasone in HepG2 cellsFEBS Letters, 1992
- Heparins, coumarin, and bone densityThe Lancet, 1991